financetom
Business
financetom
/
Business
/
Looking At Snowflake's Recent Unusual Options Activity
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Looking At Snowflake's Recent Unusual Options Activity
Aug 14, 2025 9:28 AM

Whales with a lot of money to spend have taken a noticeably bearish stance on Snowflake.

Looking at options history for Snowflake we detected 12 trades.

If we consider the specifics of each trade, it is accurate to state that 16% of the investors opened trades with bullish expectations and 50% with bearish.

From the overall spotted trades, 4 are puts, for a total amount of $472,570 and 8, calls, for a total amount of $628,400.

What's The Price Target?

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $180.0 and $220.0 for Snowflake, spanning the last three months.

Insights into Volume & Open Interest

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Snowflake's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Snowflake's significant trades, within a strike price range of $180.0 to $220.0, over the past month.

Snowflake Call and Put Volume: 30-Day Overview

Biggest Options Spotted:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
SNOW PUT SWEEP NEUTRAL 09/19/25 $30.2 $29.85 $30.2 $220.00 $205.3K 1.5K 69
SNOW PUT SWEEP BEARISH 09/19/25 $30.2 $29.85 $30.2 $220.00 $181.2K 1.5K 69
SNOW CALL SWEEP BEARISH 09/05/25 $13.7 $13.55 $13.55 $195.00 $135.5K 547 11
SNOW CALL TRADE NEUTRAL 12/19/25 $25.45 $24.7 $25.13 $195.00 $125.6K 792 30
SNOW CALL SWEEP BULLISH 01/16/26 $23.25 $23.05 $23.25 $200.00 $95.3K 3.9K 43

About Snowflake

Founded in 2012, Snowflake is a fully managed platform that consolidates data hosted on different public clouds for centralized analytics and governance. Snowflake's cloud-native architecture allows users to independently scale the compute and storage layers, providing customers with optimized performance at lower costs. The company's data lake and data warehouse products support a variety of use cases, including business analytics, data engineering, and artificial intelligence. Snowflake is widely used by Fortune 2000 companies in financial services, media, and retail sectors.

Following our analysis of the options activities associated with Snowflake, we pivot to a closer look at the company's own performance.

Present Market Standing of Snowflake

Currently trading with a volume of 1,113,888, the SNOW's price is down by -1.45%, now at $194.03.

RSI readings suggest the stock is currently may be approaching oversold.

Anticipated earnings release is in 13 days.

Expert Opinions on Snowflake

3 market experts have recently issued ratings for this stock, with a consensus target price of $257.0.

Turn $1000 into $1270 in just 20 days?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.

* Consistent in their evaluation, an analyst from JMP Securities keeps a Market Outperform rating on Snowflake with a target price of $260.

* Reflecting concerns, an analyst from Stephens & Co. lowers its rating to Overweight with a new price target of $261.

* An analyst from UBS persists with their Buy rating on Snowflake, maintaining a target price of $250.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Snowflake, Benzinga Pro gives you real-time options trades alerts.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved